Țară: Armenia
Limbă: engleză
Sursă: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
drospirenone, ethinylestradiol, levomefolate calcium
Bayer Weimar GmbH & Co. KG
G03AA12
drospirenone, ethinylestradiol, levomefolate calcium
3mg+30mcg+451mcg
tablets film-coated
(28/21+7/) (orange and light orange) in blister
Prescription
Registered
2018-07-31
l,l}ICTI'YKqtr' tro M{q4nrrcMy nInM enno n.n!Fb.'Ho.o cDca4la t?r.rEA, Ilrloc {YAPINAo ILUS) i , Mlr.ryxrpo&o. nomfttrDsu np.cnrp.HoH + 3fttrE6paauor + (Mlqrx e@dcdonrr Td6n.m, nonpasre nrcso{ro{ o6.noRo[ I(al@ op!frddrd6neno, nd(l)ew n ekqtut o6dnog&4 soAepaxr: 3mnDmcr?aeon (B Duc 6ru.(o Mrram) 0,030 Mf lCfu@nqoM.Oord 0,451F Bcn*Mmu*u. @ut@Ed: Jhnoed MorcBllar, nr(pokptcnnnq4(M aqtr@or.q, ftposhpkdndr Harpr!, r4poxc(lllonrrudfldo3a, MrRi.r.dpal O6om-M ra6ldnr InnpoNoroe!, MGp.tu, d000, un r, o1!tr0 atrorc'u (E 1?t), Mea okcsr npacsrn G 172), psa otr*! xetrsn 0l 172). Ka@i .rrrc-opdsrcror t6tdk.' no(parAt m.no*on o6orcqrclli olcPxrr: R d o tb at@& be r 4qe.ttt a : td@8r Morcmnpd, nt*poryno'M@cftd ldmnoa' 4dchlns,oa trr?u, ( nmxcdDon{,uM o6;nowa 1a6nnr rb Dovsrea, q@omn 6000, d!t, mEo eorcrr (E l?'). eBa oxcsn spac{HI G l?2)i ri'4i owra xdtulr (E I72) Otrrc.trrc opuehe kaatennt, n^pbtnbe ,r.toflon a6o^a4ant xpfini\e lbtxslnlMue r'iorw. roroErc mqocr.il o6do@fi, opdrn.toro @* Hi oaon tupoHc d6'au ! nposnrbHoM cflilamre rdryDnporuro (Y+r C@Mo-opa'Neoue tnatud^a rcx?btfut tuaawbn a5o@arc't tprMLE AronrcsdrvrE m6neru; noxprEE nrero-ftor o6doc(od cDflo_optH{eloro !bd0 Ho oaHon @poHc E6r9@ s npstnlH.r d@.!ryandrc tNrtoBHpoBrto dv1+) Oopd otp.t BrncMttrpYtto (onrqom&@ cp{qBd l6u6{dr!0tmnroc (soqro'€n + r4nrt! i x P ! { l / ! 0 r i i t l { l ot.ai . / { 0 ! t s al | )r\ttttlltlL././ /0 t,J / A OapNhKonorf rcofl rc o'oft crni ,pmalllnrcc - nkdn@xroMrnoe Motrooaryde rcu6,H"poqujjo tronpouonddHoe rckdpmftHcoe .pead8o, cocronrqce m mpyoH{oncp*arHx , rmaewr6n 6ntu(, con.p)hurx Korrarr ftboNedonor I(odll)aldnDHlln d,Om r.xoposonrcm cpq;n rp's!@ rrnroc odfti6ru.u ni 4au o!.ncr4tr psnHcrm FKropoN, H*r6oncc Bu!!u rx rotop ,qlootrHp4ox, uo!@"rl r comb ncmladcHtrotu cpqela tpho. IrEc, n repaneBrrqccKotl imnonapor.rrrsrr I lM.p.$sn nmxMrHcporoxoprtrkoHnH!tutr .DoficrbaM( ofi rc r.dorcrprryq rclroi.nrisxj 3'!'!.ro8 rE o6ecn.qMa npdc@p ony qapM.kdonl.en npoqnrL, olcB 6,x.trtrri k nrodlm ecNdsRoro yMcPcHH6r aMrMrnepMoiogrrolAlre .Bo[c Citiți documentul complet
HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE YARINA PLUS SAFELY AND EFFECTIVELY.SEE FULL PRESCRIBING INFORMATION FOR YARINA PLUS. YARINA PLUS(drospirenone/ethinyl estradiol/levomefolate calciumtablets and levomefolate calciumtablets), for oral use INITIAL U.S. APPROVAL:2010 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WOMEN OVER 35 YEARS OLD WHO SMOKE SHOULD NOT USE YARINA PLUS. (4) CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVE (COC) USE. (4) ------------------------------RECENT MAJOR CHANGES---------------------- Contraindications (4) x/201x Warnings and Precautions (5.5) MM/YY ----------------------------INDICATIONS AND USAGE--------------------------- Yarina Plus is an estrogen/progestin COC containing a folate, indicated for use by women to: Prevent pregnancy. (1.1) Raisefolate levels in women who choose to use an oral contraceptive for contraception. (1.2) ---------------------DOSAGE AND ADMINISTRATION---------------------- Take one tablet daily by mouth at the same time everyday. (2.1) Tablets must be taken in the order directed on the blister pack. (2.1) ---------------------DOSAGE FORMS AND STRENGTHS---------------------- Yarina Plus consists of 28 film-coated, biconvex tablets in the following order (3): 21 orange tablets, each containing3 mg drospirenone (DRSP), 0.03 mg ethinyl estradiol (EE)as betadex clathrate and 0.451 mg levomefolate calcium, 7 light orange tablets, each containing 0.451 mg levomefolate calcium -------------------------------CONTRAINDICATIONS------------------------------ Renal impairment (4) Adrenal insufficiency (4) A high risk of arterial or venous thrombotic diseases (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer or other estrogen- or progestin-sensitive cancer (4) Liver tumors or liver disease (4) Pregnancy (4) Citiți documentul complet